About Us
Bioklone Biotech Private Limited is an ISO 9001:2015 certified bio service provider that specializes in the development of customized antibodies and assays. It has over 300 clients across various sectors including academia, R&D divisions of hospitals, diagnostic and pharma companies, in India and abroad. Ever since its inception in 2006, the vision of Bioklone has been to be among the preferred antibody companies in the world. Bioklone was awarded “Best Custom Antibody Development Specialists-India” award in Global Health and Pharma-Technology awards 2019. This recognition has been possible because of the company’s unique selling propositions including its end-to-end services, customer centric approach, timely deliveries, high quality and reliable services.
Bioklone has successfully developed custom polyclonal and monoclonal antibodies to over 1000 antigens including proteins, peptides, polysaccharides, drugs, small molecules and whole cells.
Among the several challenging antibodies developed by Bioklone, are the highly specific antibodies to modifications at certain amino acids along the target protein, including acetylation, methylation, cleavage, mutation and phosphorylation. In addition, Bioklone has developed custom antibodies to several vaccines, biomarkers for conditions including cancers, myocardial infarction, genetic disorders and rare diseases as well as plant, veterinary and human pathogens. As a contract research organization, Bioklone offers end-to-end services, including peptide designing, gene cloning, expression and purification of recombinant proteins, development of antibodies in rabbits, mice and chicken, purification and labelling of antibodies and development of assays for the antibody users. Bioklone has vast experience in the development of pharmacokinetic (PK) and anti-drug antibody (ADA) assays for study and assessment of new biosimilars and drug candidates as well as in vitro assays using cell-lines to study cell viability/proliferation.
Bioklone’s Founder and Managing Director, Dr. K. Rajeshwari has over 30 years of experience in the development of antibodies and assays. Though straightforward, the development of antibodies is capital, time, skill and labour intensive process. Having interacted with several scientists before the inception of Bioklone, Dr. Rajeshwari has an in-depth understanding of the actual needs of the antibody users as well as the struggles and challenges of the end users when the antibodies do not show desired results in their applications. Leveraging this knowledge, to ensure success of the antibodies developed at Bioklone, Rajeshwari has designed a series of strategies to actively engage the clients in the custom antibody development process, throughout the course of the project. The key to Bioklone’s success is its scientific and innovative approach in the execution of all the projects. This has been possible because of the experienced technical team at Bioklone, which pays attention to finer details and executes the projects with unerring precision. The major contributing factors for the efficient performance of Bioklone’s team are the company’s positive work ambience, backed by its state-of-the-art laboratory facilities including its well-equipped cell culture rooms and animal house.
The biggest challenge in the antibody market is the suitability of a developed antibody in the end user applications. Bioklone strongly believes that the quality of an antibody largely depends on the way it is validated. Validation of an antibody has to be done in an application-specific manner. To ensure that its antibodies give the desired binding in the end-user applications, Bioklone focuses on a highly interactive approach which involves transfer of data and test samples to the clients at specific milestones of the project. This allows the clients to validate the antibodies in their applications before closure of the project. This has been the primary reason for Bioklone to win the confidence of its clients, for repeat orders from them and for its expanding clientele. Bioklone’s antibodies and services have been cited in several international publications. Bioklone is known as a reliable antibody partner who is vested in the success of its projects. Despite the struggles and challenges in the antibody development and validation, the company continuously strives to adhere to its commitment and quality, even if it has to go the extra mile.
Management
Dr. K. Rajeshwari
Founder and Managing Director
Dr. K. Rajeshwari has over 30 years’ experience in the field of hybridoma technology and has successfully generated antibodies to several small molecules, peptides and proteins before setting up Bioklone. After completing her Ph.D. in Biochemistry from Indian Institute of Science (IISc), Bangalore,
Dr. Rajeshwari was a Post-doctoral Fellow at Thomas Jefferson University, Philadelphia, USA and a Visiting Fellow at Tata Institute of Fundamental Research (TIFR), Mumbai. Dr. Rajeshwari also carries out the role of Chief Technologist at Bioklone.
T. Venkataramani
Co-founder and Director
T. Venkataramani has over 35 years’ experience in management and technology. Venkataramani completed his M.E. from Pune University and MBA from Jamnalal Bajaj Institute of Management Sciences, Mumbai. Venkataramani handles the finance and marketing functions at Bioklone.
Our Mission
To provide cost-effective, highly interactive and end-user centric antibody and assay development services to life science researchers.
Our Vision
To be the preferred choice of scientists for antibodies and assay development solutions and to be a global player in the development of antibodies and assays for research, diagnostic and pharmaceutical applications.
